Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation (CONVINCE)

16 lutego 2022 zaktualizowane przez: Nicholas Hing Yee Liang, Clinical Research Centre, Malaysia

Effective Public Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation: A Randomized Controlled Experiment

This is a randomised controlled experiment in the form of a web based survey study which randomly exposes participants to different forms of public health messages, after which participants will be assessed on their intent to take up the COVID-19 vaccine, recommend the vaccine, and also willingness to propagate the exposed message.

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

5784

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Selangor
      • Shah Alam, Selangor, Malezja, 40170
        • Institute for Clinical Research, National Institutes of Health, Malaysia

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Willing and able to give informed consent for participation in the trial
  • Malaysian nationality.
  • Can understand either the English or Malay language.
  • Aged 18 years or above

Exclusion Criteria:

  • Received at least one COVID-19 vaccination dose

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Inny
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Descriptive Norm (70%)

Intervention in the form of a message likened to a social media post. Composed of 3 parts:

  1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)
  2. Message content describing that about 70% of Malaysians have expressed acceptance for the COVID-19 vaccine.
  3. Rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Eksperymentalny: Descriptive Norm

Intervention in the form of a message likened to a social media post. Composed of 3 parts:

  1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)
  2. Message content describing that the COVID-19 vaccine has been widely tested including with the elderly and people with existing health conditions, while subsequently highlighting that the vaccine was already received by millions worldwide.
  3. Rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Eksperymentalny: Healthcare worker (HCW) recommendation

Intervention in the form of a message likened to a social media post. Composed of 3 parts:

  1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)
  2. Message content highlights recommendation from Malaysian healthcare workers to get the vaccine, since majority of them has already received it, including the Malaysian Health Director General
  3. Rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Eksperymentalny: Negative attribute framing

Intervention in the form of a message likened to a social media post. Composed of 3 parts:

  1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)
  2. Message content describing the rate of side effects occurring with COVID-19 vaccination in a negative frame.
  3. Rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Eksperymentalny: Positive attribute framing

Intervention in the form of a message likened to a social media post. Composed of 3 parts:

  1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)
  2. Message content describing the rate of side effects occurring with COVID-19 vaccination in a positive frame.
  3. Rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Eksperymentalny: Risky choice framing (Safety)

Intervention in the form of a message likened to a social media post. Composed of 3 parts:

  1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)
  2. Message content describing a risky choice frame which compares the death rates occurring with COVID-19 vaccination versus contracting the virus itself.
  3. Rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Eksperymentalny: Risky choice framing (Side effects)

Intervention in the form of a message likened to a social media post. Composed of 3 parts:

  1. Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)
  2. Message content describing a risky choice frame that compares the incidence rates of blood clots occurring with COVID-19 vaccination versus contracting COVID-19.
  3. Rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Eksperymentalny: Control message
Control message containing only rally slogan: "It's safe and effective!"
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Eksperymentalny: Combination message: Descriptive Norm (70%) + Descriptive Norm
Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Eksperymentalny: Combination message: Descriptive Norm (70%) + HCW recommendation
Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Eksperymentalny: Combination message: Descriptive Norm (70%) + Negative attribute framing
Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Eksperymentalny: Combination message: Descriptive Norm (70%) + Positive attribute framing
Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Eksperymentalny: Combination message: Descriptive Norm (70%) + Risky choice framing (Safety)
Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Eksperymentalny: Combination message: Descriptive Norm (70%) + Risky choice framing (Side effects)
Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in intent to accept the COVID-19 vaccine amongst the Malaysian adult population.
Ramy czasowe: Immediately before and after message exposure during questionnaire administration.
Outcome measure was assessed using a questionnaire answered through a 4 point ordinal scale. Scale ranges from '"Definitely no", "Not sure, but probably no", "Not sure, but probably yes"to Definitely yes".
Immediately before and after message exposure during questionnaire administration.
Change in intent to recommend the COVID-19 vaccine to healthy adults.
Ramy czasowe: Immediately before and after message exposure during questionnaire administration.
Outcome measure was assessed using a questionnaire answered through a 5 point ordinal scale. Scale ranges from "Strongly disagree", "Disagree", "Not sure", "Agree", and "Strongly agree".
Immediately before and after message exposure during questionnaire administration.
Change in intent to recommend the COVID-19 vaccine to elderly.
Ramy czasowe: Immediately before and after message exposure during questionnaire administration.
Outcome measure was assessed using a questionnaire answered through a 5 point ordinal scale. Scale ranges from "Strongly disagree", "Disagree", "Not sure", "Agree", and "Strongly agree".
Immediately before and after message exposure during questionnaire administration.
Change in intent to recommend the COVID-19 vaccine to people with existing health conditions.
Ramy czasowe: Immediately before and after message exposure during questionnaire administration.
Outcome measure was assessed using a questionnaire answered through a 5 point ordinal scale. Scale ranges from "Strongly disagree", "Disagree", "Not sure", "Agree", and "Strongly agree".
Immediately before and after message exposure during questionnaire administration.
Intent to share message on social media platform.
Ramy czasowe: Immediately after message exposure during questionnaire administration.
Outcome measure was assessed using a questionnaire answered through a 5 point ordinal scale.Scale ranges from "Strongly disagree", "Disagree", "Not sure", "Agree", and "Strongly agree".
Immediately after message exposure during questionnaire administration.

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Moderators of vaccination intent.
Ramy czasowe: Immediately after message exposure during questionnaire administration.
Outcome measure assessed using a series of questions answered through a 5 point ordinal scale. Scale ranges from "Strongly disagree", "Disagree", "Not sure", "Agree", and "Strongly agree".
Immediately after message exposure during questionnaire administration.
Reliability of various information sources about COVID-19.
Ramy czasowe: Immediately after message exposure during questionnaire administration.
Outcome measure assessed using a questionnaire that list out various types of information sources and having participants to rate the reliability for each source using a 5 point ordinal scale. Scale ranges from "Strongly not reliable", "Not reliable, "Not sure", "Reliable", and "Strongly reliable".
Immediately after message exposure during questionnaire administration.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

29 kwietnia 2021

Zakończenie podstawowe (Rzeczywisty)

7 czerwca 2021

Ukończenie studiów (Rzeczywisty)

7 czerwca 2021

Daty rejestracji na studia

Pierwszy przesłany

10 lutego 2022

Pierwszy przesłany, który spełnia kryteria kontroli jakości

16 lutego 2022

Pierwszy wysłany (Rzeczywisty)

17 lutego 2022

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

17 lutego 2022

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

16 lutego 2022

Ostatnia weryfikacja

1 lutego 2022

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj